BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sandborn WJ, Hanauer SB. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians. Am J Gastroenterol. 2002;97:2962-2972. [PMID: 12492177 DOI: 10.1111/j.1572-0241.2002.07093.x] [Cited by in Crossref: 138] [Cited by in F6Publishing: 130] [Article Influence: 7.3] [Reference Citation Analysis]
Number Citing Articles
1 Itaba S, Iwasa T, Sadamoto Y, Nasu T, Misawa T, Inoue K, Shimokawa H, Nakamura K, Takayanagi R. Pneumocystis Pneumonia During Combined Therapy of Infliximab, Corticosteroid, and Azathioprine in a Patient with Crohn’s Disease. Dig Dis Sci 2007;52:1438-41. [DOI: 10.1007/s10620-006-9575-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
2 Antonioli DA. Pediatric inflammatory bowel disease. Pediatr Dev Pathol. 2005;8:2-19. [PMID: 15717115 DOI: 10.1007/s10024-004-0511-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
3 Franchimont N, Putzeys V, Collette J, Vermeire S, Rutgeerts P, De Vos M, Van Gossum A, Franchimont D, Fiasse R, Pelckmans P, Malaise M, Belaiche J, Louis E. Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease. Aliment Pharmacol Ther. 2004;20:607-614. [PMID: 15352908 DOI: 10.1111/j.1365-2036.2004.02152.x] [Cited by in Crossref: 58] [Cited by in F6Publishing: 46] [Article Influence: 3.2] [Reference Citation Analysis]
4 Sandborn WJ, Targan SR. Biologic therapy of inflammatory bowel disease. Gastroenterology. 2002;122:1592-1608. [PMID: 12016425 DOI: 10.1053/gast.2002.33426] [Cited by in Crossref: 226] [Cited by in F6Publishing: 198] [Article Influence: 11.3] [Reference Citation Analysis]
5 de Vries HS, van Oijen MG, Driessen RJ, de Jong EM, Creemers MC, Kievit W, de Jong DJ. Appropriate infliximab infusion dosage and monitoring: results of a panel meeting of rheumatologists, dermatologists and gastroenterologists. Br J Clin Pharmacol 2011;71:7-19. [PMID: 21143496 DOI: 10.1111/j.1365-2125.2010.03760.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
6 Gamarra RM, Mcgraw SD, Drelichman VS, Maas LC. Serum sickness-like reactions in patients receiving intravenous infliximab. The Journal of Emergency Medicine 2006;30:41-4. [DOI: 10.1016/j.jemermed.2005.01.033] [Cited by in Crossref: 46] [Cited by in F6Publishing: 37] [Article Influence: 2.9] [Reference Citation Analysis]
7 Iesalnieks I, Kilger A, Glass H, Obermeier F, Agha A, Schlitt HJ. Perforating Crohn's ileitis: delay of surgery is associated with inferior postoperative outcome. Inflamm Bowel Dis 2010;16:2125-30. [PMID: 20848506 DOI: 10.1002/ibd.21303] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
8 Dhillon S, Loftus EV. Medical Therapy of Crohn's Disease. Curr Treat Options Gastroenterol 2005;8:19-30. [PMID: 15625031 DOI: 10.1007/s11938-005-0048-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
9 Guidi L, Costanzo M, Ciarniello M, De Vitis I, Pioli C, Gatta L, Pace L, Tricerri A, Bartoloni C, Coppola L, Balistreri P, Doria G, Fedeli G, Gasbarrini GB. Increased levels of NF-kappaB inhibitors (IkappaBalpha and IkappaBgamma) in the intestinal mucosa of Crohn's disease patients during infliximab treatment. Int J Immunopathol Pharmacol 2005;18:155-64. [PMID: 15698520 DOI: 10.1177/039463200501800116] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
10 Ehlers S. Role of tumour necrosis factor (TNF) in host defence against tuberculosis: implications for immunotherapies targeting TNF. Ann Rheum Dis 2003;62 Suppl 2:ii37-42. [PMID: 14532147 DOI: 10.1136/ard.62.suppl_2.ii37] [Cited by in Crossref: 32] [Cited by in F6Publishing: 45] [Article Influence: 1.7] [Reference Citation Analysis]
11 de Vries HS, van Oijen MG, van Hoven-van Loo KE, de Jong DJ. Monitoring vital signs during infusion with infliximab does neither indicate nor predict development of acute infusion reactions. J Clin Gastroenterol 2009;43:387-8. [PMID: 18987555 DOI: 10.1097/MCG.0b013e318178d938] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
12 Crouser ED, Lozanski G, Fox CC, Hauswirth DW, Raveendran R, Julian MW. The CD4 + Lymphopenic Sarcoidosis Phenotype Is Highly Responsive to Anti-Tumor Necrosis Factor-α Therapy. Chest 2010;137:1432-5. [DOI: 10.1378/chest.09-2576] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
13 Falaiye TO, Mitchell KR, Lu Z, Saville BR, Horst SN, Moulton DE, Schwartz DA, Wilson KT, Rosen MJ. Outcomes following infliximab therapy for pediatric patients hospitalized with refractory colitis-predominant IBD. J Pediatr Gastroenterol Nutr 2014;58:213-9. [PMID: 24048170 DOI: 10.1097/MPG.0b013e3182a98df2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 2.1] [Reference Citation Analysis]
14 Aberra FN, Lichtenstein GR. Infliximab in ulcerative colitis. Gastroenterol Clin North Am 2006;35:821-36. [PMID: 17129815 DOI: 10.1016/j.gtc.2006.09.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
15 Chiba M, Akashi T, Ando H, Matsuhashi T, Kato J. Three Japanese cases of inflammatory bowel disease associated with left-sided colonic diverticulosis: its implication. Inflamm Bowel Dis 2005;11:952-4. [PMID: 16189430 DOI: 10.1097/01.mib.0000183427.41587.92] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
16 Tsiodras S, Samonis G, Boumpas DT, Kontoyiannis DP. Fungal Infections Complicating Tumor Necrosis Factor α Blockade Therapy. Mayo Clinic Proceedings 2008;83:181-94. [DOI: 10.4065/83.2.181] [Cited by in Crossref: 37] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
17 Hehlgans T, Pfeffer K. The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology. 2005;115:1-20. [PMID: 15819693 DOI: 10.1111/j.1365-2567.2005.02143.x] [Cited by in Crossref: 542] [Cited by in F6Publishing: 507] [Article Influence: 31.9] [Reference Citation Analysis]
18 Iqbal M, Kolodney MS. Acne fulminans with synovitis-acne-pustulosis-hyperostosis-osteitis (SAPHO) syndrome treated with infliximab. Journal of the American Academy of Dermatology 2005;52:S118-20. [DOI: 10.1016/j.jaad.2004.09.006] [Cited by in Crossref: 67] [Cited by in F6Publishing: 48] [Article Influence: 3.9] [Reference Citation Analysis]
19 Bamias G, Clark DJ, Rivera-Nieves J. Leukocyte traffic blockade as a therapeutic strategy in inflammatory bowel disease. Curr Drug Targets 2013;14:1490-500. [PMID: 23621509 DOI: 10.2174/13894501113149990158] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
20 Campi P, Benucci M, Manfredi M, Demoly P. Hypersensitivity reactions to biological agents with special emphasis on tumor necrosis factor-alpha antagonists. Curr Opin Allergy Clin Immunol 2007;7:393-403. [PMID: 17873578 DOI: 10.1097/ACI.0b013e3282ef96df] [Cited by in Crossref: 34] [Cited by in F6Publishing: 4] [Article Influence: 2.4] [Reference Citation Analysis]
21 Mizushima T, Ito T, Kishi D, Kai Y, Tamagawa H, Nezu R, Kiyono H, Matsuda H. Therapeutic effects of a new lymphocyte homing reagent FTY720 in interleukin-10 gene-deficient mice with colitis. Inflamm Bowel Dis 2004;10:182-92. [PMID: 15290910 DOI: 10.1097/00054725-200405000-00002] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 2.7] [Reference Citation Analysis]
22 Pallai A, Kiss B, Vereb G, Armaka M, Kollias G, Szekanecz Z, Szondy Z. Transmembrane TNF-α Reverse Signaling Inhibits Lipopolysaccharide-Induced Proinflammatory Cytokine Formation in Macrophages by Inducing TGF-β: Therapeutic Implications. J Immunol. 2016;196:1146-1157. [PMID: 26729808 DOI: 10.4049/jimmunol.1501573] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]
23 Seddik M, Meliez H, Seguy D, Viget N, Cortot A, Colombel JF. Pneumocystis Jiroveci (Carinii) Pneumonia Following Initiation of Infliximab and Azathioprine Therapy in a Patient With Crohnʼs Disease: . Inflammatory Bowel Diseases 2004;10:436-7. [DOI: 10.1097/00054725-200407000-00017] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]
24 Sugiura F, Kojima T, Oba M, Tsuchiya H, Ishiguro N. Anaphylactic reaction to infliximab in two rheumatoid arthritis patients who had previously received infliximab and resumed. Modern Rheumatology 2014;15:201-3. [DOI: 10.3109/s10165-005-0386-x] [Cited by in Crossref: 8] [Article Influence: 1.0] [Reference Citation Analysis]
25 Present DH. Crohn’s fistula: current concepts in management1 1Abbreviations used in this paper: EUA, examination under anesthesia; EUS, endoscopic ultrasound; MP, mercaptopurine; MRI, magnetic resonance imaging. Gastroenterology 2003;124:1629-35. [DOI: 10.1016/s0016-5085(03)00392-5] [Cited by in Crossref: 45] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
26 Miehsler W, Novacek G, Wenzl H, Vogelsang H, Knoflach P, Kaser A, Dejaco C, Petritsch W, Kapitan M, Maier H. A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease. J Crohns Colitis. 2010;4:221-256. [PMID: 21122513 DOI: 10.1016/j.crohns.2009.12.001] [Cited by in Crossref: 60] [Cited by in F6Publishing: 55] [Article Influence: 5.0] [Reference Citation Analysis]
27 Sachar DB. Ten Common Errors in the Management of Inflammatory Bowel Disease: . Inflammatory Bowel Diseases 2003;9:205-9. [DOI: 10.1097/00054725-200305000-00011] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.0] [Reference Citation Analysis]
28 Sartor R. Episodic retreatment versus scheduled maintenance therapy of Crohn’s disease with infliximab: Not so far apart. Gastroenterology 2004;126:598-601. [DOI: 10.1053/j.gastro.2003.12.019] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 1.5] [Reference Citation Analysis]
29 Segarra Cantón O, Infante Pina D, Tormo Carnicé R. [Infliximab therapy for inflammatory bowel disease: seven years on]. An Pediatr (Barc) 2007;67:344-51. [PMID: 17949644 DOI: 10.1016/s1695-4033(07)70652-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
30 Comerford LW, Bickston SJ. Treatment of luminal and fistulizing Crohn's disease with infliximab. Gastroenterol Clin North Am. 2004;33:387-406, xi. [PMID: 15177545 DOI: 10.1016/j.gtc.2004.02.014] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
31 Sou S, Matsui T, Yao T, Yorioka M, Tsuda S, Kikuchi Y, Wada Y, Nagahama T, Yao K. CLINICAL AND ENDOSCOPIC HEALING AFTER INFLIXIMAB TREATMENT IN PATIENTS WITH CROHN's DISEASE. Dig Endosc 2006;18:29-33. [DOI: 10.1111/j.1443-1661.2006.00566.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
32 Venkova K, Keith JC, Meerveld BG. Oral Treatment with Recombinant Human Interleukin-11 Improves Mucosal Transport in the Colon of Human Leukocyte Antigen-B27 Transgenic Rats. J Pharmacol Exp Ther 2004;308:206-13. [DOI: 10.1124/jpet.103.058701] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
33 Swaminath A, Kornbluth A. Optimizing drug therapy in inflammatory bowel disease. Curr Gastroenterol Rep 2007;9:513-20. [DOI: 10.1007/s11894-007-0068-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
34 Rampton DS. Preventing TB in patients with Crohn's disease needing infliximab or other anti-TNF therapy. Gut 2005;54:1360-2. [PMID: 16113045 DOI: 10.1136/gut.2005.076034] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 1.7] [Reference Citation Analysis]
35 West ES, Nanda K, Ofodile O, Rutledge J, Brandling-Bennett HA. Adalimumab-Induced Cutaneous Lupus Erythematosus in a 16-Year-Old Girl with Juvenile Idiopathic Arthritis. Pediatr Dermatol 2015;32:e140-4. [PMID: 25845414 DOI: 10.1111/pde.12576] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
36 Colombel JF, Loftus EV Jr, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, Zinsmeister AR, Sandborn WJ. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology. 2004;126:19-31. [PMID: 14699483 DOI: 10.1053/j.gastro.2003.10.047] [Cited by in Crossref: 638] [Cited by in F6Publishing: 556] [Article Influence: 35.4] [Reference Citation Analysis]
37 Colombel JF, Loftus EV Jr, Tremaine WJ, Pemberton JH, Wolff BG, Young-Fadok T, Harmsen WS, Schleck CD, Sandborn WJ. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol 2004;99:878-83. [PMID: 15128354 DOI: 10.1111/j.1572-0241.2004.04148.x] [Cited by in Crossref: 275] [Cited by in F6Publishing: 231] [Article Influence: 15.3] [Reference Citation Analysis]
38 van der Hagen SJ, Baeten CG, Soeters PB, Russel MG, Beets-Tan RG, van Gemert WG. Anti-TNF-alpha (infliximab) used as induction treatment in case of active proctitis in a multistep strategy followed by definitive surgery of complex anal fistulas in Crohn's disease: a preliminary report. Dis Colon Rectum. 2005;48:758-767. [PMID: 15750797 DOI: 10.1007/s10350-004-0828-0] [Cited by in Crossref: 66] [Cited by in F6Publishing: 52] [Article Influence: 3.9] [Reference Citation Analysis]
39 Miheller P, Lakatos PL, Horváth G, Molnár T, Szamosi T, Czeglédi Z, Salamon A, Czimmer J, Rumi G, Palatka K, Papp M, Jakab Z, Szabó A, Gelley A, Lakatos L, Barta Z, Balázs C, Rácz I, Zeher M, Döbrönte Z, Altorjay I, Hunyady B, Simon L, Papp J, Banai J, Nagy F, Lonovics J, Ujszászy L, Muzes G, Herszényi L, Tulassay Z. Efficacy and safety of infliximab induction therapy in Crohn's Disease in Central Europe--a Hungarian nationwide observational study. BMC Gastroenterol 2009;9:66. [PMID: 19740450 DOI: 10.1186/1471-230X-9-66] [Cited by in Crossref: 24] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
40 Chiba M, Tsuji T, Nakane K, Tsuda S, Ishii H, Ohno H, Obara Y, Komatsu M, Tozawa H. High Remission Rate with Infliximab and Plant-Based Diet as First-Line (IPF) Therapy for Severe Ulcerative Colitis: Single-Group Trial. Perm J 2020;24:1-10. [PMID: 33482946 DOI: 10.7812/TPP/19.166] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
41 Nanavati SA, Ergun GA, Schwartz JT. Avoiding Infliximab in The Treatment of Crohn's Disease in Patients With Multiple Sclerosis. American Journal of Gastroenterology 2003;98:2333-4. [DOI: 10.1111/j.1572-0241.2003.07727.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
42 Katz LH, Kopylov U, Fudim E, Yavzori M, Picard O, Ungar B, Eliakim R, Ben-Horin S, Chowers Y. Expression of IL-2, IL-17 and TNF-alpha in patients with Crohn’s disease treated with anti-TNF antibodies. Clin Res Hepatol Gastroenterol. 2014;38:491-498. [PMID: 24613656 DOI: 10.1016/j.clinre.2014.01.010] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
43 Papachristou GI, Plevy S. Novel biologics in inflammatory bowel disease. Gastroenterol Clin North Am 2004;33:251-69, ix. [PMID: 15177537 DOI: 10.1016/j.gtc.2004.02.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
44 Caprilli R, Angelucci E, Cocco A, Viscido A, Zippi M. Efficacy of conventional immunosuppressive drugs in IBD. Digestive and Liver Disease 2004;36:766-80. [DOI: 10.1016/j.dld.2004.06.014] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
45 de la Fuente Penco B, Marcó Piella A, Riera Mestre A, Boadas Mir J. Sepsis por Listeria monocytogenes asociada al uso de infliximab. Medicina Clínica 2005;124:398. [DOI: 10.1157/13072579] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
46 Richter JA, Bickston SJ. Infliximab use in luminal Crohn's disease. Gastroenterol Clin North Am 2006;35:775-93. [PMID: 17129813 DOI: 10.1016/j.gtc.2006.09.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
47 Ball SL, Suwara MI, Borthwick LA, Wilson JA, Mann DA, Fisher AJ. How reliable are sino-nasal cell lines for studying the pathophysiology of chronic rhinosinusitis? Ann Otol Rhinol Laryngol 2015;124:437-42. [PMID: 25539661 DOI: 10.1177/0003489414565003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
48 Adegbola SO, Sahnan K, Tozer PJ, Phillips RK, Faiz OD, Warusavitarne J, Hart A. Review of local injection of anti-TNF for perianal fistulising Crohn's disease. Int J Colorectal Dis. 2017;32:1539-1544. [PMID: 28900730 DOI: 10.1007/s00384-017-2899-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
49 Travassos WJ, Cheifetz AS. Infliximab: Use in Inflammatory Bowel Disease. Curr Treat Options Gastroenterol. 2005;8:187-196. [PMID: 15913508 DOI: 10.1007/s11938-005-0011-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 1.3] [Reference Citation Analysis]
50 Lichtenstein L, Ron Y, Kivity S, Ben-Horin S, Israeli E, Fraser GM, Dotan I, Chowers Y, Confino-Cohen R, Weiss B. Infliximab-Related Infusion Reactions: Systematic Review. J Crohns Colitis. 2015;9:806-815. [PMID: 26092578 DOI: 10.1093/ecco-jcc/jjv096] [Cited by in Crossref: 97] [Cited by in F6Publishing: 72] [Article Influence: 13.9] [Reference Citation Analysis]
51 Mahmoud NN, Halwani Y, Montbrun SD, Shah PM, Hedrick TL, Rashid F, Schwartz DA, Dalal RL, Kamiński JP, Zaghiyan K, Fleshner PR, Weissler JM, Fischer JP. Current management of perianal Crohn’s disease. Current Problems in Surgery 2017;54:262-98. [DOI: 10.1067/j.cpsurg.2017.02.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
52 Nielsen OH, Seidelin JB, Munck LK, Rogler G. Use of biological molecules in the treatment of inflammatory bowel disease. J Intern Med. 2011;270:15-28. [PMID: 21241384 DOI: 10.1111/j.1365-2796.2011.02344.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
53 Kozuch PL, Hanauer SB. Treatment of inflammatory bowel disease: A review of medical therapy. World J Gastroenterol 2008; 14(3): 354-377 [PMID: 18200659 DOI: 10.3748/wjg.14.354] [Cited by in CrossRef: 137] [Cited by in F6Publishing: 128] [Article Influence: 9.8] [Reference Citation Analysis]
54 Goldenberg BA, Rawsthorne P, Bernstein CN. The utility of 6-thioguanine metabolite levels in managing patients with inflammatory bowel disease. Am J Gastroenterol. 2004;99:1744-1748. [PMID: 15330913 DOI: 10.1111/j.1572-0241.2004.30415.x] [Cited by in Crossref: 72] [Cited by in F6Publishing: 67] [Article Influence: 4.0] [Reference Citation Analysis]
55 Soto-Fernández S, González-Carro P, De Pedro-Esteban A, Legaz-Huidobro ML, Pérez-Roldán F, Roncero García-Escribano O, Valbuena-González M, Ruiz-Carrillo F. [Infliximab-induced hepatitis in a patient with Crohn's disease]. Gastroenterol Hepatol 2006;29:321-2. [PMID: 16733041 DOI: 10.1157/13087475] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 0.6] [Reference Citation Analysis]
56 Chowdhury M, Kudara N, Chiba T, Endo M, Akasaka R, Tomita K, Fujiwara S, Mizutani T, Sugai T, Takikawa Y, Suzuki K. Evaluation of Infliximab Effects on Gastrointestinal Bleeding in Crohn's Disease Using Double-Balloon Endoscopy. Case Rep Gastroenterol 2009;3:193-7. [PMID: 21103274 DOI: 10.1159/000224712] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
57 Hanauer SB. Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk? Gut 2007;56:1181-3. [PMID: 17698862 DOI: 10.1136/gut.2006.115980] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 2.4] [Reference Citation Analysis]
58 Sibartie V, Kirwan WO, O'Mahony S, Stack W, Shanahan F. Intestinal tuberculosis mimicking Crohn's disease: lessons relearned in a new era. Eur J Gastroenterol Hepatol 2007;19:347-9. [PMID: 17353702 DOI: 10.1097/MEG.0b013e328012122b] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
59 Bremner AR, Griffiths DM, Beattie RM. Current therapy of ulcerative colitis in children. Expert Opin Pharmacother 2004;5:37-53. [PMID: 14680434 DOI: 10.1517/14656566.5.1.37] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
60 Danese S, Semeraro S, Papa A, Roberto I, Scaldaferri F, Fedeli G, Gasbarrini G, Gasbarrini A. Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol. 2005;11:7227-7236. [PMID: 16437620 DOI: 10.3748/wjg.v11.i46.7227] [Cited by in CrossRef: 202] [Cited by in F6Publishing: 171] [Article Influence: 12.6] [Reference Citation Analysis]
61 Rypens F, Dubois J, Garel L. The place of interventional radiology in Crohn disease in children. Pediatr Radiol 2007;37:1093-5. [PMID: 17899061 DOI: 10.1007/s00247-007-0560-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
62 Hibi T, Sakuraba A, Watanabe M, Motoya S, Ito H, Sato N, Yoshinari T, Motegi K, Kinouchi Y, Takazoe M, Suzuki Y, Matsumoto T, Kawakami K, Matsumoto T, Hirata I, Tanaka S, Ashida T, Matsui T. C-reactive protein is an indicator of serum infliximab level in predicting loss of response in patients with Crohn’s disease. J Gastroenterol 2014;49:254-62. [DOI: 10.1007/s00535-013-0807-0] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 4.8] [Reference Citation Analysis]
63 Roskos LK, Davis CG, Schwab GM. The clinical pharmacology of therapeutic monoclonal antibodies. Drug Dev Res 2004;61:108-20. [DOI: 10.1002/ddr.10346] [Cited by in Crossref: 74] [Cited by in F6Publishing: 37] [Article Influence: 4.1] [Reference Citation Analysis]
64 Mcnamara D, Brophy S, Hyland J. Perianal Crohn's disease and infliximab therapy. The Surgeon 2004;2:258-63. [DOI: 10.1016/s1479-666x(04)80094-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
65 Reiling N, Schneider D, Ehlers S. Mycobacterium Tuberculosis-Induced Cell Death of Primary Human Monocytes and Macrophages Is Not Significantly Modulated by Tumor Necrosis Factor-Targeted Biologicals. Journal of Investigative Dermatology Symposium Proceedings 2007;12:26-33. [DOI: 10.1038/sj.jidsymp.5650033] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
66 Di Sabatino A, Rosado MM, Cazzola P, Biancheri P, Tinozzi FP, Laera MR, Cantoro L, Vanoli A, Carsetti R, Corazza GR. Splenic function and IgM-memory B cells in Crohn's disease patients treated with infliximab. Inflamm Bowel Dis. 2008;14:591-596. [PMID: 18240280 DOI: 10.1002/ibd.20374] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
67 Chiba M, Tanaka Y, Ono I. Early intestinal obstruction after infliximab therapy in Crohn's disease. Autops Case Rep 2019;9:e2018068. [PMID: 30863735 DOI: 10.4322/acr.2018.068] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
68 Losco A, Gianelli U, Cassani B, Baldini L, Conte D, Basilisco G. Epstein-Barr virus-associated lymphoma in Crohn’s disease. Inflamm Bowel Dis. 2004;10:425-429. [PMID: 15475752 DOI: 10.1097/00054725-200407000-00015] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 1.7] [Reference Citation Analysis]
69 Orlando A, Mocciaro F, Civitavecchia G, Scimeca D, Cottone M. Minimizing infliximab toxicity in the treatment of inflammatory bowel disease. Digestive and Liver Disease 2008;40:S236-46. [DOI: 10.1016/s1590-8658(08)60532-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
70 Kaazan P, Tan Z, Maiyani P, Mickenbecker M, Edwards S, Mcivor C, Andrews JM. Weight and BMI Patterns in a Biologicals-Treated IBD Cohort. Dig Dis Sci. [DOI: 10.1007/s10620-022-07488-7] [Reference Citation Analysis]
71 Seddik M, Melliez H, Seguy D, Viget N, Cortot A, Colombel JF. Pneumocystis jiroveci (carinii) pneumonia after initiation of infliximab and azathioprine therapy in a patient with Crohn’s disease. Inflamm Bowel Dis. 2005;11:618-620. [PMID: 15905713 DOI: 10.1097/01.mib.0000164002.32735.c2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
72 García-Arranz M, Herreros MD, González-Gómez C, de la Quintana P, Guadalajara H, Georgiev-Hristov T, Trébol J, Garcia-Olmo D. Treatment of Crohn's-Related Rectovaginal Fistula With Allogeneic Expanded-Adipose Derived Stem Cells: A Phase I-IIa Clinical Trial. Stem Cells Transl Med 2016;5:1441-6. [PMID: 27412883 DOI: 10.5966/sctm.2015-0356] [Cited by in Crossref: 68] [Cited by in F6Publishing: 55] [Article Influence: 11.3] [Reference Citation Analysis]
73 Ardizzone S, Bianchi Porro G. Biologic Therapy for Inflammatory Bowel Disease: . Drugs 2005;65:2253-86. [DOI: 10.2165/00003495-200565160-00002] [Cited by in Crossref: 178] [Cited by in F6Publishing: 178] [Article Influence: 10.5] [Reference Citation Analysis]
74 Fischer M, Campbell SC, Calley CSJ, Helper DJ, Chiorean MV, Fadda HM. Risk Factors for Rescue Therapy in Crohn’s Patients Maintained on Infliximab After Withdrawal of the Immunomodulator: A Long-Term Follow-Up. Dig Dis Sci 2017;62:3131-7. [DOI: 10.1007/s10620-017-4771-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
75 Blonski W, Lichtenstein GR. Safety of biologics in inflammatory bowel disease. Curr Treat Options Gastroenterol 2006;9:221-33. [PMID: 16901386 DOI: 10.1007/s11938-006-0041-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
76 Lin J, Ziring D, Desai S, Kim S, Wong M, Korin Y, Braun J, Reed E, Gjertson D, Singh RR. TNFalpha blockade in human diseases: an overview of efficacy and safety. Clin Immunol 2008;126:13-30. [PMID: 17916445 DOI: 10.1016/j.clim.2007.08.012] [Cited by in Crossref: 156] [Cited by in F6Publishing: 149] [Article Influence: 10.4] [Reference Citation Analysis]
77 Yeckes AR, Hoffenberg EJ. Rapid Infliximab Infusions in Pediatric Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology & Nutrition 2009;49:151-4. [DOI: 10.1097/mpg.0b013e31818e1914] [Cited by in Crossref: 18] [Cited by in F6Publishing: 1] [Article Influence: 1.4] [Reference Citation Analysis]
78 Kozuch PL, Hanauer SB. General Principles and Pharmacology of Biologics in Inflammatory Bowel Disease. Gastroenterology Clinics of North America 2006;35:757-73. [DOI: 10.1016/j.gtc.2006.09.005] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
79 Fow J, Grossman S. A comprehensive guide to patient-focused management strategies for Crohn disease. Gastroenterol Nurs 2007;30:93-8; quiz 98-100. [PMID: 17440309 DOI: 10.1097/01.SGA.0000267927.77545.bd] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
80 D'haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, De Vos M, van Deventer S, Stitt L, Donner A, Vermeire S, Van De Mierop FJ, Coche JR, van der Woude J, Ochsenkühn T, van Bodegraven AA, Van Hootegem PP, Lambrecht GL, Mana F, Rutgeerts P, Feagan BG, Hommes D. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. The Lancet 2008;371:660-7. [DOI: 10.1016/s0140-6736(08)60304-9] [Cited by in Crossref: 845] [Cited by in F6Publishing: 252] [Article Influence: 60.4] [Reference Citation Analysis]
81 West RL, van der Woude CJ, Hansen BE, Felt-Bersma RJ, van Tilburg AJ, Drapers JA, Kuipers EJ. Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn's disease with infliximab: a double-blind placebo-controlled study. Aliment Pharmacol Ther. 2004;20:1329-1336. [PMID: 15606395 DOI: 10.1111/j.1365-2036.2004.02247.x] [Cited by in Crossref: 148] [Cited by in F6Publishing: 113] [Article Influence: 8.7] [Reference Citation Analysis]
82 McCormick M, Cushman G. Happiness When the Body Hurts: Achieving Well-Being in Chronic Health Conditions. Child Adolesc Psychiatr Clin N Am 2019;28:147-56. [PMID: 30832949 DOI: 10.1016/j.chc.2018.11.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
83 Lichtenstein GR, Abreu MT, Cohen R, Tremaine W; American Gastroenterological Association. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006;130:940-987. [PMID: 16530532 DOI: 10.1053/j.gastro.2006.01.048] [Cited by in Crossref: 328] [Cited by in F6Publishing: 303] [Article Influence: 20.5] [Reference Citation Analysis]
84 Caprilli R, Angelucci E, Clemente V. Recent advances in the management of Crohn's disease. Digestive and Liver Disease 2008;40:709-16. [DOI: 10.1016/j.dld.2008.02.042] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
85 Dinesen L, Travis S. Targeting nanomedicines in the treatment of Crohn's disease: focus on certolizumab pegol (CDP870). Int J Nanomedicine 2007;2:39-47. [PMID: 17722511 DOI: 10.2147/nano.2007.2.1.39] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
86 Gustot T, Lemmers A, Louis E, Nicaise C, Quertinmont E, Belaiche J, Roland S, Van Gossum A, Devière J, Franchimont D. Profile of soluble cytokine receptors in Crohn's disease. Gut 2005;54:488-95. [PMID: 15753533 DOI: 10.1136/gut.2004.043554] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 3.1] [Reference Citation Analysis]
87 Casellas i Jordà F. [TNF-alpha inhibitors in inflammatory bowel disease]. Med Clin (Barc) 2004;123:627-34. [PMID: 15546523 DOI: 10.1016/s0025-7753(04)74622-9] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
88 Vultaggio A, Petroni G, Pratesi S, Nencini F, Cammelli D, Ferraro A, Maggi E, Matucci A. How the immune system responds to therapeutic biological agents. J Int Med Res 2016;44:38-42. [PMID: 27683137 DOI: 10.1177/0300060515593248] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
89 de Ridder L, Benninga MA, Taminiau JA, Hommes DW, van Deventer SJ. Infliximab use in children and adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;45:3-14. [PMID: 17592358 DOI: 10.1097/MPG.0b013e31803e171c] [Cited by in Crossref: 28] [Cited by in F6Publishing: 3] [Article Influence: 1.9] [Reference Citation Analysis]
90 Feldman PA, Wolfson D, Barkin JS. Medical management of Crohn's disease. Clin Colon Rectal Surg 2007;20:269-81. [PMID: 20011423 DOI: 10.1055/s-2007-991026] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
91 Posner J, Barrington P, Brier T, Datta-Mannan A. Monoclonal Antibodies: Past, Present and Future. Handb Exp Pharmacol 2019;260:81-141. [PMID: 31820172 DOI: 10.1007/164_2019_323] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
92 Rivera-Nieves J, Gorfu G, Ley K. Leukocyte adhesion molecules in animal models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14:1715-1735. [PMID: 18523998 DOI: 10.1002/ibd.20501] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 3.3] [Reference Citation Analysis]
93 Colombel JF, Ricart E, Loftus EV, Tremaine WJ, Young-Fadok T, Dozois EJ, Wolff BG, Devine R, Pemberton JH, Sandborn WJ. Management of Crohn’s disease of the ileoanal pouch with infliximab. Am J Gastroenterol. 2003;98:2239-2244. [PMID: 14572574 DOI: 10.1111/j.1572-0241.2003.07675.x] [Cited by in Crossref: 121] [Cited by in F6Publishing: 89] [Article Influence: 6.4] [Reference Citation Analysis]
94 de Vries HS, van Oijen MG, de Jong DJ. Serious events with infliximab in patients with inflammatory bowel disease: a 9-year cohort study in the Netherlands. Drug Saf 2008;31:1135-44. [PMID: 19026030 DOI: 10.2165/0002018-200831120-00009] [Cited by in Crossref: 34] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
95 Sandborn WJ. Optimizing anti-tumor necrosis factor strategies in inflammatory bowel disease. Curr Gastroenterol Rep 2003;5:501-5. [DOI: 10.1007/s11894-003-0040-8] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 1.7] [Reference Citation Analysis]
96 Chiba M, Tsuji T, Nakane K, Tsuda S, Ishii H, Ohno H, Watanabe K, Ito M, Komatsu M, Sugawara T. Induction with Infliximab and a Plant-Based Diet as First-Line (IPF) Therapy for Crohn Disease: A Single-Group Trial. Perm J 2017;21:17-009. [PMID: 29035182 DOI: 10.7812/TPP/17-009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
97 Han PD, Cohen RD. Managing immunogenic responses to infliximab: treatment implications for patients with Crohn's disease. Drugs. 2004;64:1767-1777. [PMID: 15301561 DOI: 10.2165/00003495-200464160-00004] [Cited by in Crossref: 54] [Cited by in F6Publishing: 46] [Article Influence: 3.0] [Reference Citation Analysis]
98 Teng X, Xu LF, Zhou P, Sun HW, Sun M. Effects of trefoil peptide 3 on expression of TNF-alpha, TLR4, and NF-kappaB in trinitrobenzene sulphonic acid induced colitis mice. Inflammation 2009;32:120-9. [PMID: 19238529 DOI: 10.1007/s10753-009-9110-x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 2.5] [Reference Citation Analysis]
99 Blonski W, Lichtenstein GR. Safety of biologic therapy: . Inflammatory Bowel Diseases 2007;13:769-96. [DOI: 10.1002/ibd.20027] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
100 Byeon JS, Choi EK, Heo NY, Hong SC, Myung SJ, Yang SK, Kim JH, Song JK, Yoo B, Yu CS. Antitumor necrosis factor-alpha therapy for early postoperative recurrence of gastrointestinal Behçet’s disease: report of a case. Dis Colon Rectum. 2007;50:672-676. [PMID: 17216141 DOI: 10.1007/s10350-006-0813-x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 2.0] [Reference Citation Analysis]
101 Byrne CM, Solomon MJ, Young JM, Selby W, Harrison JD. Patient Preferences Between Surgical and Medical Treatment in Crohn's Disease. Diseases of the Colon & Rectum 2007;50:586-97. [DOI: 10.1007/s10350-006-0847-0] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
102 Hommel KA, McGrady ME, Peugh J, Zacur G, Loreaux K, Saeed S, Williams E, Denson LA. Longitudinal Patterns of Medication Nonadherence and Associated Health Care Costs. Inflamm Bowel Dis 2017;23:1577-83. [PMID: 28617754 DOI: 10.1097/MIB.0000000000001165] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
103 Matsumoto T, Iida M, Kohgo Y, Imamura A, Kusugami K, Nakano H, Fujiyama Y, Matsu T, Hibi T. Therapeutic efficacy of infliximab on active Crohn's disease under nutritional therapy. Scandinavian Journal of Gastroenterology 2009;40:1423-30. [DOI: 10.1080/00365520510023639] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
104 Otley A, Critch J, Butzner JD. Infliximab for the treatment of paediatric Crohn's disease: Obstacles to accessing a necessary therapy. Paediatr Child Health 2004;9:87-9. [PMID: 19654986 DOI: 10.1093/pch/9.2.87] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
105 Swaminath A, Ullman T, Rosen M, Mayer L, Lichtiger S, Abreu MT. Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab-treated and naïve patients. Aliment Pharmacol Ther. 2009;29:273-278. [PMID: 19006540 DOI: 10.1111/j.1365-2036.2008.03878.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 2.1] [Reference Citation Analysis]
106 Yeh S, Nussenblatt RB, Levy-Clarke GA. Emerging biologics in the treatment of uveitis. Expert Rev Clin Immunol 2007;3:781-96. [PMID: 20477028 DOI: 10.1586/1744666X.3.5.781] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
107 Borrelli O, Bascietto C, Viola F, Bueno de Mesquita M, Barbato M, Mancini V, Bosco S, Cucchiara S. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease. Dig Liver Dis. 2004;36:342-347. [PMID: 15191204 DOI: 10.1016/j.dld.2003.12.014] [Cited by in Crossref: 116] [Cited by in F6Publishing: 107] [Article Influence: 6.4] [Reference Citation Analysis]
108 Chiba M, Abe T, Tsuda H, Sugawara T, Tsuda S, Tozawa H, Fujiwara K, Imai H. Lifestyle-related disease in Crohn’s disease: Relapse prevention by a semi-vegetarian diet. World J Gastroenterol 2010; 16(20): 2484-2495 [PMID: 20503448 DOI: 10.3748/wjg.v16.i20.2484] [Cited by in CrossRef: 110] [Cited by in F6Publishing: 100] [Article Influence: 9.2] [Reference Citation Analysis]
109 Tsiodras S, Samonis G, Boumpas DT, Kontoyiannis DP. Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin Proc. 2008;83:181-194. [PMID: 18241628 DOI: 10.1016/s0025-6196(11)60839-2] [Cited by in Crossref: 196] [Cited by in F6Publishing: 2] [Article Influence: 14.0] [Reference Citation Analysis]
110 Laine L, Hanauer SB. Considerations in the management of steroid-dependent Crohn’s disease. Gastroenterology 2003;125:906-10. [DOI: 10.1016/s0016-5085(03)01129-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
111 Maggi E, Vultaggio A, Matucci A. Acute infusion reactions induced by monoclonal antibody therapy. Expert Rev Clin Immunol. 2011;7:55-63. [PMID: 21162650 DOI: 10.1586/eci.10.90] [Cited by in Crossref: 76] [Cited by in F6Publishing: 72] [Article Influence: 6.9] [Reference Citation Analysis]
112 Kaklamanos M, Thomas D, Pikazis D, Kaltsas G. Thyroid-specific changes following treatment with biological therapies in patients with rheumatic diseases. Endocrine 2015;50:146-53. [PMID: 25690756 DOI: 10.1007/s12020-015-0551-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
113 Solem CA, Loftus EV Jr. Management of refractory inflammatory bowel disease. Gastroenterol Clin North Am 2004;33:319-34, x. [PMID: 15177541 DOI: 10.1016/j.gtc.2004.02.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
114 Matsuda C, Ito T, Song J, Mizushima T, Tamagawa H, Kai Y, Hamanaka Y, Inoue M, Nishida T, Matsuda H, Sawa Y. Therapeutic effect of a new immunosuppressive agent, everolimus, on interleukin-10 gene-deficient mice with colitis. Clin Exp Immunol 2007;148:348-59. [PMID: 17437423 DOI: 10.1111/j.1365-2249.2007.03345.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 2.2] [Reference Citation Analysis]
115 Lecluse LL, Piskin G, Mekkes JR, Bos JD, de Rie MA. Review and expert opinion on prevention and treatment of infliximab-related infusion reactions. Br J Dermatol 2008;159:527-36. [PMID: 18627374 DOI: 10.1111/j.1365-2133.2008.08728.x] [Cited by in Crossref: 64] [Cited by in F6Publishing: 58] [Article Influence: 4.6] [Reference Citation Analysis]
116 Rufo PA, Bousvaros A. Current therapy of inflammatory bowel disease in children. Paediatr Drugs 2006;8:279-302. [PMID: 17037946 DOI: 10.2165/00148581-200608050-00002] [Cited by in Crossref: 71] [Cited by in F6Publishing: 56] [Article Influence: 4.7] [Reference Citation Analysis]
117 Jwa YJ, Kim N, Park HJ, Park JS, Bae WK, Kim K, Lee JS, Moon YS. A Case of Psoriasis Induced by Infliximab Treatment for Crohn's Disease. Korean J Gastroenterol 2010;56:324. [DOI: 10.4166/kjg.2010.56.5.324] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
118 Lu J, Van Stappen T, Spasic D, Delport F, Vermeire S, Gils A, Lammertyn J. Fiber optic-SPR platform for fast and sensitive infliximab detection in serum of inflammatory bowel disease patients. Biosens Bioelectron. 2016;79:173-179. [PMID: 26706938 DOI: 10.1016/j.bios.2015.11.087] [Cited by in Crossref: 70] [Cited by in F6Publishing: 56] [Article Influence: 10.0] [Reference Citation Analysis]
119 Di Sabatino A, Ciccocioppo R, Armellini E, Morera R, Ricevuti L, Cazzola P, Fulle I, Corazza GR. Serum bFGF and VEGF correlate respectively with bowel wall thickness and intramural blood flow in Crohn’s disease. Inflamm Bowel Dis. 2004;10:573-577. [PMID: 15472517 DOI: 10.1097/00054725-200409000-00011] [Cited by in Crossref: 58] [Cited by in F6Publishing: 56] [Article Influence: 3.2] [Reference Citation Analysis]
120 Sandborn WJ, Fazio VW, Feagan BG, Hanauer SB;  American Gastroenterological Association Clinical Practice Committee. AGA technical review on perianal Crohn's disease. Gastroenterology. 2003;125:1508-1530. [PMID: 14598268 DOI: 10.1016/j.gastro.2003.08.025] [Cited by in Crossref: 389] [Cited by in F6Publishing: 291] [Article Influence: 20.5] [Reference Citation Analysis]
121 Ally MR, Betteridge JD, Veerappan GR. Delayed hypersensitivity reaction with infliximab: unusual to occur after initial dose. Inflamm Bowel Dis 2012;18:E1592-3. [PMID: 22231796 DOI: 10.1002/ibd.21909] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
122 Chiba M, Tsuda S, Tsuji T, Nakane K, Komatsu M, Miura Y, Ishida T, Shibahara T, Nishimoto T. Crohn's disease successfully treated with infliximab in a patient receiving hemodialysis: case report and review of the literature. Medicine (Baltimore) 2014;93:e54. [PMID: 25101989 DOI: 10.1097/MD.0000000000000054] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
123 Blonski W, Lichtenstein GR. Complications of biological therapy for inflammatory bowel diseases. Curr Opin Gastroenterol 2006;22:30-43. [PMID: 16319674 DOI: 10.1097/01.mog.0000196151.74819.8e] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 1.6] [Reference Citation Analysis]
124 Hough RE, Snowden JA, Wulffraat NM. Haemopoietic stem cell transplantation in autoimmune diseases: a European perspective. British Journal of Haematology 2005;128:432-59. [DOI: 10.1111/j.1365-2141.2004.05298.x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 54] [Article Influence: 3.7] [Reference Citation Analysis]
125 Orenstein R. Travel in patients receiving TNF-alpha inhibitors. Travel Med Infect Dis 2005;3:105-9. [PMID: 17292013 DOI: 10.1016/j.tmaid.2004.08.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
126 de Ridder L, Escher JC, Bouquet J, Schweizer JJ, Rings EHHM, Tolboom JJM, Houwen RHJ, Norbruis OF, Derkx BHF, Taminiau JAJM. Infliximab Therapy in 30 Patients With Refractory Pediatric Crohn Disease With and Without Fistulas in The Netherlands: . Journal of Pediatric Gastroenterology and Nutrition 2004;39:46-52. [DOI: 10.1097/00005176-200407000-00010] [Cited by in Crossref: 68] [Cited by in F6Publishing: 58] [Article Influence: 3.8] [Reference Citation Analysis]
127 Papa A, Mocci G, Bonizzi M, Felice C, Andrisani G, De Vitis I, Guidi L, Gasbarrini A. Use of infliximab in particular clinical settings: management based on current evidence. Am J Gastroenterol. 2009;104:1575-1586. [PMID: 19491875 DOI: 10.1038/ajg.2009.162] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
128 Haennig A, Staumont G, Lepage B, Faure P, Alric L, Buscail L, Bournet B, Moreau J. The results of seton drainage combined with anti-TNFα therapy for anal fistula in Crohn’s disease. Colorectal Dis. 2015;17:311-319. [PMID: 25425534 DOI: 10.1111/codi.12851] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
129 Rimola J, Rodríguez S, García-Bosch O, Ricart E, Pagès M, Pellisé M, Ayuso C, Panés J. Role of 3.0-T MR colonography in the evaluation of inflammatory bowel disease. Radiographics. 2009;29:701-719. [PMID: 19448111 DOI: 10.1148/rg.293085115] [Cited by in Crossref: 37] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
130 Sandborn WJ, Faubion WA. Biologics in inflammatory bowel disease: how much progress have we made? Gut 2004;53:1366-73. [PMID: 15306602 DOI: 10.1136/gut.2003.025452] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 2.3] [Reference Citation Analysis]
131 Hommes DW, van Deventer SJ. Targeting tumor necrosis factor-α in inflammatory bowel disease: why, how, and when? Current Opinion in Gastroenterology 2003;19:350-7. [DOI: 10.1097/00001574-200307000-00005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
132 Hibi T, Sakuraba A, Watanabe M, Motoya S, Ito H, Motegi K, Kinouchi Y, Takazoe M, Suzuki Y, Matsumoto T, Kawakami K, Matsumoto T, Hirata I, Tanaka S, Ashida T, Matsui T. Retrieval of serum infliximab level by shortening the maintenance infusion interval is correlated with clinical efficacy in Crohn's disease. Inflamm Bowel Dis 2012;18:1480-7. [PMID: 21987418 DOI: 10.1002/ibd.21886] [Cited by in Crossref: 39] [Cited by in F6Publishing: 42] [Article Influence: 3.5] [Reference Citation Analysis]
133 Benoit S, Toksoy A, Brocker E, Gillitzer R, Goebeler M. Treatment of recalcitrant pustular psoriasis with infliximab: effective reduction of chemokine expression. Br J Dermatol 2004;150:1009-12. [DOI: 10.1111/j.1365-2133.2004.05960.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 2.4] [Reference Citation Analysis]
134 Matsumoto T, Iida M, Motoya S, Haruma K, Suzuki Y, Kobayashi K, Ito H, Miyata M, Kusunoki M, Chiba T, Yamamoto S, Hibi T. Therapeutic Efficacy of Infliximab on Patients with Short Duration of Crohn's Disease: A Japanese Multicenter Survey. Diseases of the Colon & Rectum 2008;51:916-23. [DOI: 10.1007/s10350-008-9241-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]